Core Non Current Liabilities Total vs Short Term Debt Analysis
CLB Stock | USD 20.27 0.71 3.63% |
Core Laboratories financial indicator trend analysis is way more than just evaluating Core Laboratories prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Core Laboratories is a good investment. Please check the relationship between Core Laboratories Non Current Liabilities Total and its Short Term Debt accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Core Laboratories NV. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.
Non Current Liabilities Total vs Short Term Debt
Non Current Liabilities Total vs Short Term Debt Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Core Laboratories Non Current Liabilities Total account and Short Term Debt. At this time, the significance of the direction appears to have fragmental relationship.
The correlation between Core Laboratories' Non Current Liabilities Total and Short Term Debt is 0.46. Overlapping area represents the amount of variation of Non Current Liabilities Total that can explain the historical movement of Short Term Debt in the same time period over historical financial statements of Core Laboratories NV, assuming nothing else is changed. The correlation between historical values of Core Laboratories' Non Current Liabilities Total and Short Term Debt is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Non Current Liabilities Total of Core Laboratories NV are associated (or correlated) with its Short Term Debt. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Short Term Debt has no effect on the direction of Non Current Liabilities Total i.e., Core Laboratories' Non Current Liabilities Total and Short Term Debt go up and down completely randomly.
Correlation Coefficient | 0.46 |
Relationship Direction | Positive |
Relationship Strength | Weak |
Non Current Liabilities Total
Short Term Debt
Most indicators from Core Laboratories' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Core Laboratories current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Core Laboratories NV. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. As of December 12, 2024, Selling General Administrative is expected to decline to about 34.6 M. In addition to that, Tax Provision is expected to decline to about 4 M
2021 | 2022 | 2023 | 2024 (projected) | Gross Profit | 83.8M | 78.9M | 94.0M | 171.1M | Total Revenue | 470.3M | 489.7M | 509.8M | 619.3M |
Core Laboratories fundamental ratios Correlations
Click cells to compare fundamentals
Core Laboratories Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Core Laboratories fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 774.7M | 568.6M | 580.9M | 578.4M | 586.4M | 550.2M | |
Short Long Term Debt Total | 381.8M | 327.0M | 250.3M | 222.4M | 215.4M | 220.2M | |
Other Current Liab | 50.8M | 34.9M | 28.5M | 31.8M | 32.4M | 46.3M | |
Total Current Liabilities | 111.6M | 89.8M | 90.8M | 103.1M | 88.1M | 100.6M | |
Total Stockholder Equity | 182.1M | 75.6M | 161.0M | 189.0M | 224.8M | 131.8M | |
Property Plant And Equipment Net | 199.2M | 181.7M | 172.3M | 157.4M | 153.5M | 120.1M | |
Net Debt | 370.7M | 313.2M | 232.6M | 207.0M | 200.3M | 187.0M | |
Retained Earnings | 160.5M | 50.5M | 68.3M | 85.9M | 120.8M | 194.2M | |
Accounts Payable | 35.6M | 23.0M | 29.7M | 45.8M | 33.5M | 35.9M | |
Cash | 11.1M | 13.8M | 17.7M | 15.4M | 15.1M | 14.4M | |
Non Current Assets Total | 553.4M | 402.7M | 391.8M | 366.7M | 363.3M | 325.2M | |
Non Currrent Assets Other | (71.3M) | (76.9M) | (74.6M) | (73.0M) | 98.6M | 103.5M | |
Cash And Short Term Investments | 11.1M | 13.8M | 17.7M | 15.4M | 15.1M | 14.4M | |
Net Receivables | 131.6M | 83.2M | 96.8M | 106.9M | 123.1M | 129.1M | |
Common Stock Shares Outstanding | 44.6M | 45.0M | 46.7M | 46.8M | 47.5M | 40.8M | |
Liabilities And Stockholders Equity | 774.7M | 568.6M | 580.9M | 578.4M | 586.4M | 550.2M | |
Non Current Liabilities Total | 480.9M | 403.3M | 329.1M | 286.3M | 268.5M | 267.2M | |
Inventory | 50.2M | 38.2M | 45.4M | 60.4M | 71.7M | 39.7M | |
Other Current Assets | 28.4M | 30.7M | 29.1M | 28.9M | 13.2M | 26.0M | |
Other Stockholder Equity | 26.8M | 27.1M | 97.0M | 100.9M | 108.6M | 114.0M | |
Total Liab | 592.5M | 493.0M | 419.9M | 389.4M | 356.6M | 367.8M | |
Property Plant And Equipment Gross | 199.2M | 181.7M | 172.3M | 157.4M | 469.3M | 492.7M | |
Total Current Assets | 221.2M | 165.8M | 189.1M | 211.7M | 223.1M | 225.0M | |
Accumulated Other Comprehensive Income | (6.3M) | (7.2M) | (10.1M) | (3.8M) | (5.0M) | (5.2M) | |
Short Term Debt | 11.8M | 11.4M | 12.3M | 11.7M | 10.2M | 14.1M | |
Intangible Assets | 17.5M | 8.6M | 8.1M | 7.5M | 6.9M | 6.6M | |
Other Liab | 109.9M | 87.7M | 91.1M | 75.6M | 86.9M | 66.4M | |
Other Assets | 119.4M | 179.4M | 107.7M | 102.3M | 1.0 | 0.95 | |
Long Term Debt | 305.3M | 259.4M | 188.6M | 172.4M | 163.1M | 227.7M | |
Property Plant Equipment | 123.5M | 115.3M | 172.3M | 157.4M | 181.0M | 126.1M | |
Current Deferred Revenue | 13.4M | 5.5M | 7.8M | 5.9M | 4.8M | 4.5M | |
Treasury Stock | (29.4M) | (14.1M) | (4.1M) | (1.4M) | (1.6M) | (1.6M) | |
Net Tangible Assets | 11.7M | 19.6M | (58.5M) | 115.6M | 104.1M | 109.3M | |
Noncontrolling Interest In Consolidated Entity | 4.3M | 4.1M | 4.6M | 4.7M | 5.4M | 4.6M | |
Retained Earnings Total Equity | 160.5M | 50.5M | 68.3M | 85.9M | 77.4M | 73.5M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Core Laboratories offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Core Laboratories' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Core Laboratories Nv Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Core Laboratories Nv Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Core Laboratories NV. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Crypto Correlations module to use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins.
Is Oil & Gas Equipment & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Core Laboratories. If investors know Core will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Core Laboratories listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.316 | Dividend Share 0.04 | Earnings Share 0.54 | Revenue Per Share 11.158 | Quarterly Revenue Growth 0.072 |
The market value of Core Laboratories is measured differently than its book value, which is the value of Core that is recorded on the company's balance sheet. Investors also form their own opinion of Core Laboratories' value that differs from its market value or its book value, called intrinsic value, which is Core Laboratories' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Core Laboratories' market value can be influenced by many factors that don't directly affect Core Laboratories' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Core Laboratories' value and its price as these two are different measures arrived at by different means. Investors typically determine if Core Laboratories is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Core Laboratories' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.